Avalo reports 2024 net loss of $35.1M; cash of $134.5M funds into at least 2027

Avalo Therapeutics, Inc.

Cash and equivalents $134.5M at Dec 31, 2024 vs $7.4M in 2023; runway into at least 2027.
Net loss $35.1M in 2024 ($7.94 basic EPS) vs $31.5M loss in 2023; diluted EPS -$20.91.
R&D expense $24.4M, up $10.7M, driven by Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa.
Topline data from Phase 2 LOTUS trial expected in 2026; second indication for AVTX-009 planned.
Appointed Jennifer Riley as Chief Strategy Officer effective January 1, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.